{"id":"W3141372695","doi":"10.1016/s1470-2045(21)00034-6","title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":349,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fulvestrant; Medicine; Aromatase inhibitor; Internal medicine; Oncology; Breast cancer; Cancer; Cohort; Regimen; Clinical endpoint; Clinical trial; Estrogen receptor; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002448632,0.001313025,0.002592248,0.0004860409,0.0003679259,0.001304171,0.0006919882,0.001168981,0.00251498],"category_scores_gemma":[0.001665669,0.0004332487,0.002304659,0.0005312184,0.0009815631,0.001261545,0.00031729,0.002229874,0.0006026875],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111719,"about_ca_system_score_gemma":0.0008150821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001499154,"about_ca_topic_score_gemma":0.003109957,"domain_scores_codex":[0.999175,0.0004045277,0.00004176815,0.0001270418,0.00006839196,0.0001832059],"domain_scores_gemma":[0.9989355,0.0003546507,0.0002003741,0.0001450156,0.00006511289,0.0002993083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9341796,0.01058382,0.005436638,0.0005030094,0.002525562,0.0001065499,0.0001267622,0.0007854978,0.007449793,0.0001218328,0.0007600661,0.03742071],"study_design_scores_gemma":[0.6140949,0.3542387,0.02431028,0.00005858281,0.002459098,0.0002134414,0.0001322446,0.0006426694,0.001706933,0.0002440178,0.00185131,0.00004779493],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949609,0.003071714,0.0001913357,0.000171785,0.0001098648,0.0003049906,0.0004878066,0.00002186894,0.000679719],"genre_scores_gemma":[0.9937158,0.002261817,0.000456653,0.0004603232,0.0002093161,0.0003221217,0.001367775,0.00001643003,0.001189843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002592248,"threshold_uncertainty_score":0.01294976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05096464552649327,"score_gpt":0.3993410276253444,"score_spread":0.3483763820988511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}